Background Earlier SPIRIT percutaneous coronary intervention (PCI) trials with the XIENCE V everolimus-eluting stent (EES), including SPIRIT FIRST, II, III, and IV, met their prespecified primary and major secondary endpoints;…
Background The risk of gastrointestinal bleeding (GIB) is higher in patients taking dual antiplatelet therapy, but other risk factors for GIB are less well defined. Methods We compared 141 patients…
Background Percutaneous coronary intervention (PCI) via transradial approach (TRA) has emerged as an alternative and competitive method compared with transfemoral approach (TFA) for PCI in simple to complex coronary disease….
Aim To evaluate the effectiveness of the new film-forming cyanoacrylate liquid microbial sealant InteguSEAL⁎ (Kimberly-Clark) to reduce local skin bacteria contamination and bacteremia after percutaneous interventions (PI). Methods Sixty-three consecutive…
Background Coronary allograft vasculopathy (CAV) is a major cause of mortality in heart transplantation. Immunosuppressants, coronary risk factors, and statins may influence its pathogenesis. There are conflicting reports regarding the…
Background Diabetes mellitus (DM) plays a major role in the development and progression of coronary artery disease and negatively impacts clinical outcome in patients undergoing revascularization. Drug-eluting stents (DES) significantly…
Background Previous data suggests that patients presenting with acute coronary syndrome (ACS) who are on chronic clopidogrel have a poor prognosis possibly due to low response to clopidogrel. This study…
Background Little is known about the association between obesity and bleeding complications after percutaneous coronary intervention (PCI). We investigated the impact of body mass index (BMI) on PCI-related bleeding and…
Introduction While bivalirudin use in patients undergoing percutaneous coronary intervention (PCI) results in less bleeding compared to unfractionated heparin (UFH), its safety in patients undergoing rotational atherectomy (RA) is unknown….
